TERM ID="NYU_TERM_1" STRING="Clinical Excellence" FREQUENCY=1 START=377 END=396 LEMMA="CLINICAL EXCELLENCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="HER2-overexpressing breast cancer" FREQUENCY=2 START=31 END=64 LEMMA="HER2-OVEREXPRESSING BREAST CANCER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_3" STRING="HER2-overexpressing breast cancer" FREQUENCY=2 START=526 END=559 LEMMA="HER2-OVEREXPRESSING BREAST CANCER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_4" STRING="HER2-positive" FREQUENCY=1 START=1808 END=1821 LEMMA="HER2-POSITIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="ICER" FREQUENCY=1 START=2323 END=2327 LEMMA="ICER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="ICER for lapatinib" FREQUENCY=1 START=2323 END=2341 LEMMA="LAPATINIB ICER" LEMMA_FREQUENCY=1 HEAD_TERM="ICER" HEAD_LEMMA="ICER"
TERM ID="NYU_TERM_7" STRING="ICERs" FREQUENCY=2 START=2032 END=2037 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIOS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_8" STRING="ICERs" FREQUENCY=2 START=2498 END=2503 LEMMA="INCREMENTAL COST EFFECTIVENESS RATIOS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_9" STRING="Lapatinib" FREQUENCY=1 START=0 END=9 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_10" STRING="Median" FREQUENCY=1 START=1243 END=1249 LEMMA="MEDIAN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="Median progression-free survival" FREQUENCY=1 START=1425 END=1457 LEMMA="MEDIAN PROGRESSION-FREE SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="Median time" FREQUENCY=1 START=980 END=991 LEMMA="MEDIAN TIME" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="RCT" FREQUENCY=1 START=834 END=837 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_14" STRING="STA" FREQUENCY=1 START=448 END=451 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_15" STRING="anthracycline" FREQUENCY=1 START=1901 END=1914 LEMMA="ANTHRACYCLINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="base-case" FREQUENCY=1 START=1983 END=1992 LEMMA="BASE-CASE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="base-case incremental cost-effectiveness ratios" FREQUENCY=1 START=1983 END=2030 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO BASE-CASE" LEMMA_FREQUENCY=1 HEAD_TERM="incremental cost-effectiveness ratios" HEAD_LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO"
TERM ID="NYU_TERM_18" STRING="capecitabine" FREQUENCY=1 START=2762 END=2774 LEMMA="CAPECITABINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="capecitabine arm" FREQUENCY=1 START=1040 END=1056 LEMMA="CAPECITABINE ARM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="capecitabine group" FREQUENCY=1 START=1519 END=1537 LEMMA="CAPECITABINE GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="capecitabine monotherapy" FREQUENCY=2 START=2085 END=2109 LEMMA="CAPECITABINE MONOTHERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_22" STRING="capecitabine monotherapy" FREQUENCY=2 START=2374 END=2398 LEMMA="CAPECITABINE MONOTHERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_23" STRING="capecitabine monotherapy arm" FREQUENCY=1 START=1069 END=1097 LEMMA="CAPECITABINE MONOTHERAPY ARM" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="capecitabine monotherapy group" FREQUENCY=1 START=1550 END=1580 LEMMA="CAPECITABINE MONOTHERAPY GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="clinical effectiveness" FREQUENCY=1 START=146 END=168 LEMMA="CLINICAL EFFECTIVENESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="comparators" FREQUENCY=1 START=2852 END=2863 LEMMA="COMPARATOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_27" STRING="confidence interval" FREQUENCY=1 START=1109 END=1128 LEMMA="CONFIDENCE INTERVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="controlled trial" FREQUENCY=1 START=816 END=832 LEMMA="CONTROLLED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_29" STRING="cost-effectiveness" FREQUENCY=2 START=173 END=191 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_30" STRING="cost-effectiveness" FREQUENCY=2 START=2725 END=2743 LEMMA="COST-EFFECTIVENESS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_31" STRING="cost-effectiveness of lapatinib" FREQUENCY=2 START=173 END=204 LEMMA="LAPATINIB COST-EFFECTIVENESS" LEMMA_FREQUENCY=2 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_32" STRING="cost-effectiveness of lapatinib" FREQUENCY=2 START=2725 END=2756 LEMMA="LAPATINIB COST-EFFECTIVENESS" LEMMA_FREQUENCY=2 HEAD_TERM="cost-effectiveness" HEAD_LEMMA="COST-EFFECTIVENESS"
TERM ID="NYU_TERM_33" STRING="disease area" FREQUENCY=1 START=1965 END=1977 LEMMA="DISEASE AREA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_34" STRING="economic model" FREQUENCY=1 START=1725 END=1739 LEMMA="ECONOMIC MODEL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="evidence review group" FREQUENCY=1 START=102 END=123 LEMMA="EVIDENCE REVIEW GROUP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="hazard ratio" FREQUENCY=3 START=1188 END=1200 LEMMA="HAZARD RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_37" STRING="hazard ratio" FREQUENCY=3 START=1372 END=1384 LEMMA="HAZARD RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_38" STRING="hazard ratio" FREQUENCY=3 START=1650 END=1662 LEMMA="HAZARD RATIO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_39" STRING="incremental cost-effectiveness ratios" FREQUENCY=2 START=1993 END=2030 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_40" STRING="incremental cost-effectiveness ratios" FREQUENCY=2 START=1993 END=2030 LEMMA="INCREMENTAL COST-EFFECTIVENESS RATIO" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_41" STRING="key parameters" FREQUENCY=1 START=2893 END=2907 LEMMA="KEY PARAMETER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="lapatinib" FREQUENCY=7 START=195 END=204 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_43" STRING="lapatinib" FREQUENCY=7 START=1025 END=1034 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_44" STRING="lapatinib" FREQUENCY=7 START=1504 END=1513 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_45" STRING="lapatinib" FREQUENCY=7 START=2043 END=2052 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_46" STRING="lapatinib" FREQUENCY=7 START=2256 END=2265 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_47" STRING="lapatinib" FREQUENCY=7 START=2332 END=2341 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_48" STRING="lapatinib" FREQUENCY=7 START=2747 END=2756 LEMMA="LAPATINIB" LEMMA_FREQUENCY=8
TERM ID="NYU_TERM_49" STRING="manufacturer" FREQUENCY=2 START=309 END=322 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_50" STRING="manufacturer" FREQUENCY=2 START=1709 END=1722 LEMMA="MANUFACTURER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_51" STRING="metastatic" FREQUENCY=1 START=502 END=512 LEMMA="METASTATIC" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_52" STRING="metastatic HER2-overexpressing breast cancer" FREQUENCY=1 START=238 END=282 LEMMA="METASTATIC HER2-OVEREXPRESSING BREAST CANCER" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_53" STRING="methodological quality" FREQUENCY=1 START=853 END=875 LEMMA="METHODOLOGICAL QUALITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_54" STRING="model outputs" FREQUENCY=1 START=2941 END=2954 LEMMA="MODEL OUTPUT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_55" STRING="progression-free" FREQUENCY=1 START=1752 END=1768 LEMMA="PROGRESSION-FREE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_56" STRING="progression-free survival" FREQUENCY=1 START=652 END=677 LEMMA="PROGRESSION-FREE SURVIVAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_57" STRING="randomised controlled trial" FREQUENCY=1 START=805 END=832 LEMMA="RANDOMISED CONTROLLED TRIAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_58" STRING="response rates" FREQUENCY=1 START=679 END=693 LEMMA="RESPONSE RATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_59" STRING="sensitivity analyses" FREQUENCY=2 START=2298 END=2318 LEMMA="SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_60" STRING="sensitivity analyses" FREQUENCY=2 START=2473 END=2493 LEMMA="SENSITIVITY ANALYSIS" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_61" STRING="single technology appraisal" FREQUENCY=1 START=419 END=446 LEMMA="SINGLE TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_62" STRING="taxane" FREQUENCY=1 START=1918 END=1924 LEMMA="TAXANE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_63" STRING="technology appraisal" FREQUENCY=1 START=426 END=446 LEMMA="TECHNOLOGY APPRAISAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_64" STRING="trastuzumab" FREQUENCY=1 START=1929 END=1940 LEMMA="TRASTUZUMAB" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_65" STRING="trastuzumab-containing regimes" FREQUENCY=2 START=2224 END=2254 LEMMA="TRASTUZUMAB-CONTAINING REGIME" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_66" STRING="trastuzumab-containing regimes" FREQUENCY=2 START=2586 END=2616 LEMMA="TRASTUZUMAB-CONTAINING REGIME" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_67" STRING="vinorelbine monotherapy" FREQUENCY=2 START=2113 END=2136 LEMMA="VINORELBINE MONOTHERAPY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_68" STRING="vinorelbine monotherapy" FREQUENCY=2 START=2402 END=2425 LEMMA="VINORELBINE MONOTHERAPY" LEMMA_FREQUENCY=2
